AbbVie secures two FDA Breakthrough Therapy designations
AbbVie said the FDA granted Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A) in colorectal cancer and non-small cell lung cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.